Effect of ACE-inhibition on coronary microvascular function and symptoms in normotensive women with microvascular angina: A randomized placebo-controlled trial.

<h4>Objective</h4>Studies have suggested a beneficial effect of angiotensin-converting enzyme (ACE) inhibition. To explore whether the ACE inhibitor ramipril has a direct effect on the microvasculature beyond the blood pressure (BP) lowering effect, we investigated whether ramipril impro...

Full description

Saved in:
Bibliographic Details
Main Authors: Marie Mide Michelsen, Anna Bay Rask, Elena Suhrs, Kristoffer Flintholm Raft, Nis Høst, Eva Prescott
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:https://storage.googleapis.com/plos-corpus-prod/10.1371/journal.pone.0196962/1/pone.0196962.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa%40plos-prod.iam.gserviceaccount.com%2F20210221%2Fauto%2Fstorage%2Fgoog4_request&X-Goog-Date=20210221T181024Z&X-Goog-Expires=3600&X-Goog-SignedHeaders=host&X-Goog-Signature=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
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<h4>Objective</h4>Studies have suggested a beneficial effect of angiotensin-converting enzyme (ACE) inhibition. To explore whether the ACE inhibitor ramipril has a direct effect on the microvasculature beyond the blood pressure (BP) lowering effect, we investigated whether ramipril improved coronary microvascular function in normotensive women with coronary microvascular dysfunction (CMD).<h4>Methods</h4>We included 63 normotensive women with angina, no epicardial stenosis>50% and CMD defined as a coronary flow velocity reserve (CFVR)<2.2 assessed by adenosine stress-echocardiography in a randomized double-blinded, superiority trial with 1:1 allocation to placebo or ramipril (maximum dose 10 mg depending on blood pressure) for 24±6 weeks. Primary outcome was CFVR. Secondary outcomes were left ventricular systolic and diastolic function and symptoms evaluated by Seattle Angina Questionnaire (clinicaltrials.gov, NCT02525081).<h4>Results</h4>Follow-up was available on 55 patients. BP remained unchanged during treatment in both groups. CFVR improved in both the ramipril (p = 0.004) and placebo group (p = 0.026) with no difference between groups (p = 0.63). Symptoms improved in both groups with no significant between-group differences. No changes were detected in parameters of systolic and diastolic function. No serious adverse reactions were reported.<h4>Conclusions</h4>In normotensive women with angina and CMD, treatment with ramipril had no significant effect on CFVR or symptoms compared with placebo. The effect of ACE inhibition previously reported may be mediated by blood pressure reduction.
ISSN:1932-6203